MedEffect Canada

As part of its regulatory responsibility, Health Canada conducts consultations in the area of post-market surveillance, primarily adverse reaction reporting, of drugs and health products. Participants' comments and ideas contribute to the development of strategic priorities for these programs, helping us define what they should strive to achieve in the short, medium and long-term.

Current Consultations

Past Consultations

2009

• Consultation on the Regulatory Amendment to the Adverse Drug Reaction Reporting Section of the Food and Drug Regulations - Canada Gazette Part I

2008

• Proposal to Amend the Food and Drug Regulations with respect to Pharmacovigilance Summary Reports
• Draft Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products

2007

• Release of Draft Guidance Document - Risk Communications under Canada's Access to Medicines Regime (CAMR)
• Draft Guidance Document - Triggers for Issuance of Risk Communication Documents for Marketed Health Products for Human Use

2006

• Draft Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products
• Draft Attestation Criteria For Consumer Advertising Preclearance Agencies
• MedEffect Canada Initiative
• Invitational Roundtable -- Risk Information Communication (Section 2.21) of the Revised Draft Consumer Advertising Guidelines for Marketed Health Products
• Second Round of External Stakeholder Consultations Revised Draft Consumer Advertising Guidelines for Marketed Health Products (for Nonprescription Drugs including Natural Health Products)

2005

• Expert Advisory Panel on selective COX-2 inhibitors NSAIDs
• Working Conference - Strengthening the Evaluation of Real World Drug Safety and Effectiveness

2001

• Drug Effectiveness / Outcomes Research Workshop

Information on other consultation activities occuring throughout Health Canada are available in the Departmental Public Involvement section.